Aptorum Group Limited

NasdaqCM:APM Stock Report

Market Cap: US$7.6m

Aptorum Group Past Earnings Performance

Past criteria checks 2/6

Aptorum Group has been growing earnings at an average annual rate of 18.6%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 0.3% per year.

Key information

18.6%

Earnings growth rate

25.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate0.3%
Return on equity-3.0%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Apr 26
We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Recent updates

Aptorum Group GAAP EPS of -$0.05

Oct 03

Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?

Jul 14
Is Aptorum Group (NASDAQ:APM) In A Good Position To Deliver On Growth Plans?

Aptorum Group: Advancing Oncology, Autoimmune & Infectious Disease Therapies

Feb 11

Aptorum inks development agreement with Exeltis

May 06

We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Apr 26
We Think Shareholders Should Be Aware Of Some Factors Beyond Aptorum Group's (NASDAQ:APM) Profit

Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?

Jan 16
Do Institutions Own Aptorum Group Limited (NASDAQ:APM) Shares?

Aptorum files for early-stage trial for ALS-4 in Canada

Dec 21

Revenue & Expenses Breakdown

How Aptorum Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:APM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240024
31 Mar 240-135
31 Dec 230-345
30 Sep 231-867
30 Jun 231-1378
31 Mar 231-1289
31 Dec 221-1089
30 Sep 221-10810
30 Jun 221-11810
31 Mar 221-18810
31 Dec 212-25811
30 Sep 211-14812
30 Jun 211-4813
31 Mar 2111812
31 Dec 2016811
30 Sep 201-5810
30 Jun 201-1699
31 Mar 201-17108
31 Dec 191-19117
30 Sep 191-19106
30 Jun 191-1894
31 Mar 190-1784
31 Dec 180-1573
30 Sep 180-1163
30 Jun 180-763
31 Mar 180-543
31 Dec 170-333

Quality Earnings: APM has a high level of non-cash earnings.

Growing Profit Margin: APM became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: APM has become profitable over the past 5 years, growing earnings by 18.6% per year.

Accelerating Growth: APM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: APM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).


Return on Equity

High ROE: APM's Return on Equity (-3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 22:37
End of Day Share Price 2024/12/31 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aptorum Group Limited is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
null nullArgus Research Company
Yue-Kwong LuiChina Renaissance Securities